Loading
Vaccine Efficacy / Vaccine Confidence / Respiratory Syncytial Virus Vaccines · Journal article
Expert Review of Vaccines · June 17, 2026
A consensus or society position rather than new primary data.
This expert review summarizes RSV disease burden in older adults and barriers to vaccine uptake, including limited awareness, lack of reimbursement, mistrust, misinformation, and inconsistent guidance. The authors advocate for life-course immunization strategies emphasizing broader benefits beyond infection prevention, such as reducing antimicrobial resistance and promoting healthy aging.
Journal article. Older adults eligible for RSV vaccination.
RSV is a leading cause of acute respiratory infection with substantial morbidity and mortality in older adults Three RSV vaccines are approved with clinical and real-world evidence supporting efficacy/effectiveness and safety Barriers to uptake include limited awareness, lack of reimbursement, mistrust, misinformation, and inconsistent guidance
No original efficacy, effectiveness, or safety data reported RSV is a leading cause of acute respiratory infection with substantial morbidity and mortality in older adults
Clinicians should recognize that improving adult RSV vaccine uptake requires addressing structural barriers (reimbursement, harmonized recommendations) and communication strategies emphasizing preservation of independence and everyday well-being. A life-course immunization approach built on trust is essential for equitable protection.
Expert commentary on barriers and strategies to improve adult RSV vaccination uptake, not reporting original efficacy or safety data.
As stated by the source record.
Clinicians should recognize that improving adult RSV vaccine uptake requires addressing structural barriers (reimbursement, harmonized recommendations) and communication strategies emphasizing preservation of independence and everyday well-being. A life-course immunization approach built on trust is essential for equitable protection.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Introduction. Respiratory syncytial virus (RSV) is a leading cause of acute respiratory infection, with substantial morbidity and mortality in older adults, yet its impact in this population remains underrecognized compared with childhood RSV. Despite the availability of effective vaccines, RSV immunization in adults is underutilized, as observed for other vaccines.Areas covered. We summarize the RSV burden in adult populations and present clinical and real-world evidence supporting efficacy/effectiveness and safety of three approved RSV vaccines. We explore barriers to adult vaccine uptake - including limited awareness, lack of reimbursement, mistrust, misinformation, and inconsistent guidance - and highlight broader benefits of adult immunization, including reducing antimicrobial resistance and promoting healthy aging. We conclude that to improve uptake, communication strategies should include messages that emphasize how vaccination prevents severe illness, preserves independence, and supports everyday well-being. We highlight that a life-course immunization strategy, built on trust, is essential to achieve equitable protection across populations.Expert opinion. Adult vaccines remain undervalued despite their proven safety and benefits, which extend beyond infection prevention to support healthy aging and reduce antimicrobial resistance. To maximize their impact, strategies such as harmonizing recommendations, improving reimbursement, leveraging digital tools, and addressing vaccine hesitancy through better communication and research are essential.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.